Logo Cencora

Cencora (COR) stock: analyst price target and their real reliability

Live quote · data updated Aug 28, 2026
Cencora · Health Care · ref. ETF XLV · 50 calls · price $321.23
💬JPI AI AssistantTry it →
What the company does: Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.

📈 Cencora (COR) stock price

$321.23+10.8% over range
Aug 28, 25low $252.74 · high $374.75Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
73% recommend buying · 11 analysts
📊 JPI status : Cencora has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →

🎯 COR price target & analyst consensusprice $321

The price target · all analysts combined (10 targets)
Highest target · 1 firm of 10$430+33.9%
Median target · of 10 targets$350+9.0%
Lowest target · 1 firm of 10$285-11.3%
Current price$321.23
Where these 10 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 990% $330 ↔ $430
Below 110% $285
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Morgan Stanley69% of its targets hit on this sector (825 calls tested). It aims for $346 (+7.7 %), call made on August 8, 2026, maturing on August 8, 2027 (20 d ago).

The 6 reliable analysts $370+15 %
The 4 other firms $345+7.2 %
How to read it: the 6 reliable firms are not filtered by optimism — 5 aim above the price, 1 below, hence their $370 median. “The 4 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 11 ratings (last 6 months)
Strong Buy00%
Buy873%
Hold327%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Cencora? The JPI assistant answers using our backtest data.

💰 Cencora dividend: yield, history & growth › open the full page

0.81%annual yield
That's ~$2.35 per share per year.

📈 Cencora fundamentals: valuation, margins & growth › open the full page

P/E 24.3Net margin 0.8 %Revenue growth +5.1 %Fairly valued

Revenue, net income and margin per year

Revenue Net income · hover a bar for details
2022
marg. 1 %
2023
Rev +10%Profit +3%
2024
Rev +12%Profit −14%
2025
Rev +9%Profit +3%

🏛️ Cencora insider buying: who's buying and how much › open the full page

2 insiders bought3 buys / 6 mo $2.3M👥 Cluster buy

🔎 Detailed analyses

🏛️ Which US Congress members hold Cencora (COR)?

2 Congress members have disclosed COR buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Jared Moskowitz · 25%Greg Landsman
→ Full members ranking (who beats the market)

✅ Historical analyst reliability on COR

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm % right i Gain vs sector i Calls i
Evercore ISI Group  100% +46.1% 2
JP Morgan  100% +30.6% 2
Barclays  100% +26.8% 2
UBS  100% +26.0% 2
Leerink Partners  100% +19.1% 2
Baird  80% +24.3% 5
Citigroup  50% +9.2% 2
Wells Fargo  50% -1.5% 2

📊 What $1,000 invested in Cencora would be worth › open the full page

In short — $1,000 invested in Cencora 10 years ago would be worth $2,729 today, i.e. +11%/yr on average. Best year: 2025 (+50%), worst: 2016 (-25%). Price performance, excluding dividends.

If I'd invested $1,000 in Cencora

InvestmentWorth todayGain
1 years ago$1,259+26%
3 years ago$1,708+71%
5 years ago$2,895+189%
→ See Cencora's full return history + gain calculator

Return by year (Cencora)

YearReturn$1,000 invested at year start
2026 (YTD)-16%$838 (-16%)
2025+50%$1,259 (+26%)
2024+9%$1,378 (+38%)
→ See Cencora's full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Cencora

Loading news…

📋 All analyst calls on COR

RBC Capital 
Aug 19, 26
■ Sector Perform neutral · not a buy · 🎯$330
Price at call : $314.69 — gap to target +5%
Today : $321.23 — gap to target +3%
🎯 on COR : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Aug 19, 27
Wells Fargo 
Aug 11, 26
▲ Overweight · 🎯$395
Price at call : $333.87 — upside +18%
Today : $321.23 — upside +23%
🎯 on COR : 50% (2 calls matureds) · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Aug 11, 27
▲ Overweight · 🎯$346
Price at call : $325 — upside +6%
Today : $321.23 — upside +8%
🎯 on COR : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Aug 7, 27
JP Morgan 
Aug 7, 26
▲ Overweight · 🎯$390
Price at call : $325 — upside +20%
Today : $321.23 — upside +21%
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Aug 7, 27
UBS 
Aug 6, 26
▲ Buy · 🎯$430
Price at call : $320.46 — upside +34%
Today : $321.23 — upside +34%
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Aug 6, 27
▲ Outperform · 🎯$350
Price at call : $320.46 — upside +9%
Today : $321.23 — upside +9%
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Aug 6, 27
■ Neutral neutral · not a buy · 🎯$285
Price at call : $286.95 — gap to target -1%
Today : $321.23 — gap to target -11%
🎯 on COR : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Jun 24, 27
Barclays 
Jun 10, 26
▲ Overweight · 🎯$350
Price at call : $281.48 — upside +24%
Today : $321.23 — upside +9%
🎯 on COR : 100% (1 call matured) · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Jun 10, 27
See the other 42 calls, newest to oldest
Wells Fargo 
May 11, 26
▲ Overweight · 🎯$331
Price at call : $259.7 — upside +27%
Today : $321.23 — upside +3%
🎯 on COR : 50% (2 calls matureds) · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : May 11, 27
UBS 
May 8, 26
▲ Buy · 🎯$412
Price at call : $261.08 — upside +58%
Today : $321.23 — upside +28%
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : May 8, 27
Citigroup 
May 7, 26
▲ Buy · 🎯$355
Price at call : $261.08 — upside +36%
Today : $321.23 — upside +11%
🎯 on COR : 0% (1 call matured) · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : May 7, 27
▲ Outperform · 🎯$300
Price at call : $261.08 — upside +15%
Today : $321.23 — upside -7%
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : May 7, 27
Baird 
May 7, 26
▲ Outperform · 🎯$339
Price at call : $255.66 — upside +33%
Today : $321.23 — upside +6%
🎯 on COR : 50% (2 calls matureds) · 📊 on Health : 51.7% · +6.5% (298 calls)
in progress (365j)
matures : May 7, 27
William Blair 
Apr 28, 26
■ Market Perform neutral · not a buy
🎯 on COR : no call matured yet · 📊 on Health : 63% · +5.2% (27 calls)
in progress (365j)
matures : Apr 28, 27
▲ Outperform · 🎯$360
Price at call : $322.46 — upside +12%
Today : $321.23 — upside +12%
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Apr 8, 27
Barclays 
Feb 13, 26
▲ Overweight · 🎯$425
Price at call : $359.97 — upside +18%
Today : $321.23 — upside +32%
🎯 on COR : 100% (1 call matured) · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 13, 27
JP Morgan 
Feb 10, 26
▲ Overweight · 🎯$419
Price at call : $365.7 — upside +15%
Today : $321.23 — upside +30%
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Feb 10, 27
Wells Fargo 
Feb 10, 26
▲ Overweight · 🎯$429
Price at call : $360 — upside +19%
Today : $321.23 — upside +34%
🎯 on COR : 50% (2 calls matureds) · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Feb 10, 27
▲ Outperform · 🎯$420
Price at call : $359.25 — upside +17%
Today : $321.23 — upside +31%
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Feb 5, 27
Morgan Stanley 
Jan 29, 26
▲ Overweight · 🎯$400
Price at call : $359.22 — upside +11%
Today : $321.23 — upside +25%
🎯 on COR : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jan 29, 27
Jefferies 
Jan 22, 26
▲ Buy · 🎯$440
Price at call : $352.47 — upside +25%
Today : $321.23 — upside +37%
🎯 on COR : no call matured yet · 📊 on Health : 50.8% · +4.5% (380 calls)
in progress (365j)
matures : Jan 22, 27
■ Neutral neutral · not a buy · 🎯$360
Price at call : $340.92 — gap to target +6%
Today : $321.23 — gap to target +12%
🎯 on COR : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Jan 5, 27
Barclays 
Dec 9, 25
▲ Overweight · 🎯$400
Price at call : $340.79 — upside +17%
Today : $321.23 — upside +25%
🎯 on COR : 100% (1 call matured) · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Dec 9, 26
JP Morgan 
Nov 11, 25
▲ Overweight · 🎯$417
Price at call : $363.42 — upside +15%
Today : $321.23 — upside +30%
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Nov 11, 26
Wells Fargo 
Nov 11, 25
▲ Overweight · 🎯$405
Price at call : $365.08 — upside +11%
Today : $321.23 — upside +26%
🎯 on COR : 50% (2 calls matureds) · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Nov 11, 26
TD Cowen 
Nov 10, 25
▲ Buy · 🎯$400
Price at call : $365.08 — upside +10%
Today : $321.23 — upside +25%
🎯 on COR : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Nov 10, 26
UBS 
Nov 7, 25
▲ Buy · 🎯$415
Price at call : $364.65 — upside +14%
Today : $321.23 — upside +29%
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Nov 7, 26
Baird 
Nov 6, 25
▲ Outperform · 🎯$395
Price at call : $360.7 — upside +10%
Today : $321.23 — upside +23%
🎯 on COR : 50% (2 calls matureds) · 📊 on Health : 51.7% · +6.5% (298 calls)
in progress (365j)
matures : Nov 6, 26
Mizuho 
Nov 6, 25
▲ Outperform · 🎯$380
Price at call : $360.24 — upside +5%
Today : $321.23 — upside +18%
🎯 on COR : no call matured yet · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Nov 6, 26
Mizuho 
Oct 30, 25
▲ Outperform · 🎯$340
Price at call : $341.21 — upside -0%
Today : $321.23 — upside +6%
🎯 on COR : no call matured yet · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Oct 30, 26
UBS 
Oct 27, 25
▲ Buy · 🎯$380
Price at call : $335.64 — upside +13%
Today : $321.23 — upside +18%
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Oct 27, 26
Mizuho 
Oct 16, 25
▲ Outperform · 🎯$334
Price at call : $319.4 — upside +5%
Today : $321.23 — upside +4%
🎯 on COR : no call matured yet · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Oct 16, 26
Wells Fargo 
Aug 13, 25
▲ Overweight · 🎯$354
Price at call : $291.04 — upside +22%
Today : $321.23 — upside +10%
Expected +22% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on COR : 50% (2 calls matureds) · 📊 on Health : 48.5% · +1.2% (392 calls)
+6.5%
stock +7% · XLV +26%
matured Aug 13, 26
Morgan Stanley 
Jul 16, 25
■ Equal-Weight neutral · not a buy · 🎯$330
Price at call : $297.83 — gap to target +11%
Today : $321.23 — gap to target +3%
🎯 on COR : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jul 16, 26
Jefferies 
Jun 30, 25
■ Hold neutral · not a buy · 🎯$300
Price at call : $295.33 — gap to target +2%
Today : $321.23 — gap to target -7%
🎯 on COR : no call matured yet · 📊 on Health : 50.8% · +4.5% (380 calls)
in progress (365j)
matures : Jun 30, 26
Wells Fargo 
Jun 3, 25
▲ Overweight · 🎯$337
Price at call : $291.55 — upside +16%
Today : $321.23 — upside +5%
Expected +16% · Actual -10% · Reason (≥ +15%) : ✗ No
🎯 on COR : 50% (2 calls matureds) · 📊 on Health : 48.5% · +1.2% (392 calls)
-9.6%
stock -10% · XLV +11%
matured Jun 3, 26
Citigroup 
May 8, 25
▲ Buy · 🎯$355
Price at call : $283 — upside +25%
Today : $321.23 — upside +11%
Expected +25% · Actual -8% · Reason (≥ +15%) : ✗ No
🎯 on COR : 0% (1 call matured) · 📊 on Health : 53.1% · +2.5% (508 calls)
-8.2%
stock -8% · XLV +8%
matured May 8, 26
Baird 
May 8, 25
▲ Outperform · 🎯$350
Price at call : $283.77 — upside +23%
Today : $321.23 — upside +9%
Expected +23% · Actual -8% · Reason (≥ +15%) : ✗ No
🎯 on COR : 50% (2 calls matureds) · 📊 on Health : 51.7% · +6.5% (298 calls)
-8.0%
stock -8% · XLV +7%
matured May 8, 26
UBS 
Apr 29, 25
▲ Buy · 🎯$335
Price at call : $292.67 — upside +14%
Today : $321.23 — upside +4%
Expected +14% · Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+5.2%
stock +5% · XLV +4%
matured Apr 29, 26
■ Neutral neutral · not a buy · 🎯$285
Price at call : $284.33 — gap to target +0%
Today : $321.23 — gap to target -11%
🎯 on COR : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Apr 11, 26
Wells Fargo 
Mar 14, 25
■ Equal-Weight neutral · not a buy · 🎯$274
Price at call : $260.96 — gap to target +5%
Today : $321.23 — gap to target -15%
🎯 on COR : 50% (2 calls matureds) · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Mar 14, 26
▲ Outperform · 🎯$280
Price at call : $247.88 — upside +13%
Today : $321.23 — upside -13%
Expected +13% · Actual +47% · Reason (≥ +15%) : ✓ Yes
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 45.8% · +0.0% (168 calls)
+46.6%
stock +47% · XLV +7%
matured Feb 6, 26
Wells Fargo 
Jan 29, 25
■ Equal-Weight neutral · not a buy · 🎯$251
Price at call : $255.94 — gap to target -2%
Today : $321.23 — gap to target -22%
🎯 on COR : 50% (2 calls matureds) · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Jan 29, 26
JP Morgan 
Jan 24, 25
▲ Overweight · 🎯$301
Price at call : $254.89 — upside +18%
Today : $321.23 — upside -6%
Expected +18% · Actual +39% · Reason (≥ +15%) : ✓ Yes
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 53.8% · +5.3% (355 calls)
+39.5%
stock +39% · XLV +7%
matured Jan 24, 26
Wells Fargo 
Dec 13, 24
■ Equal-Weight neutral · not a buy · 🎯$237
Price at call : $229.82 — gap to target +3%
Today : $321.23 — gap to target -26%
🎯 on COR : 50% (2 calls matureds) · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Dec 13, 25
Baird 
Nov 7, 24
▲ Outperform · 🎯$292
Price at call : $248.41 — upside +18%
Today : $321.23 — upside -9%
Expected +18% · Actual +47% · Reason (≥ +15%) : ✓ Yes
🎯 on COR : 50% (2 calls matureds) · 📊 on Health : 51.7% · +6.5% (298 calls)
+46.8%
stock +47% · XLV -2%
matured Nov 7, 25
UBS 
Nov 7, 24
▲ Buy · 🎯$285
Price at call : $248.41 — upside +15%
Today : $321.23 — upside -11%
Expected +15% · Actual +47% · Reason (≥ +15%) : ✓ Yes
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+46.8%
stock +47% · XLV -2%
matured Nov 7, 25
Barclays 
Nov 7, 24
▲ Overweight · 🎯$290
Price at call : $248.41 — upside +17%
Today : $321.23 — upside -10%
Expected +17% · Actual +47% · Reason (≥ +15%) : ✓ Yes
🎯 on COR : 100% (1 call matured) · 📊 on Health : 50.1% · +2.2% (629 calls)
+46.8%
stock +47% · XLV -2%
matured Nov 7, 25
▲ Outperform · 🎯$285
Price at call : $247.76 — upside +15%
Today : $321.23 — upside -11%
Expected +15% · Actual +46% · Reason (≥ +15%) : ✓ Yes
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 45.8% · +0.0% (168 calls)
+45.6%
stock +46% · XLV -2%
matured Nov 7, 25
JP Morgan 
Aug 21, 24
▲ Overweight · 🎯$287
Price at call : $240.59 — upside +19%
Today : $321.23 — upside -11%
Expected +19% · Actual +22% · Reason (≥ +15%) : ✓ Yes
🎯 on COR : 100% (2 calls matureds) · 📊 on Health : 53.8% · +5.3% (355 calls)
+21.6%
stock +22% · XLV -11%
matured Aug 21, 25

Frequently asked questions

Should I buy Cencora stock?

This isn't buy advice. For Cencora, the analyst consensus is "Buy", with an average price target of $350 (+9% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Cencora). We show the numbers — you decide.

Is it too late to buy Cencora? How high can it go?

The most bullish analyst target on Cencora is $430 (+34% above today's price); the average is $350. That's the upside they see. Check how reliable those analysts have actually been on Cencora on our site before trusting it.

Is Cencora still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 8 analysts have a real record on Cencora, the best hitting 100% over 2 calls. Current consensus: "Buy". Make your call on data, not noise.

Should you invest in Cencora? The case for and against

The arguments for and against, one by one, from the numbers: why invest in COR (and why hesitate).

What has Cencora's past performance been?

Historical returns and a "how much if I had invested" calculator: COR performance & returns.

Does Cencora pay a dividend?

Yield, consistency and growth history of the dividend: COR's dividend.

Are insiders buying COR stock?

Executives' and large holders' buys and sells, decoded: insider buying on COR.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)